𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antiviral resistance and hepatitis B therapy

✍ Scribed by Marc G. Ghany; Edward C. Doo

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
311 KB
Volume
49
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Antiviral efficacy of combination therap
Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance
✍ Hyo-Joon Yang; Jeong-Hoon Lee; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Suk Lee πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 172 KB

## Abstract There is little clinical information on the management of hepatitis B virus (HBV) that is resistant to multiple drugs including entecavir (ETV). The present retrospective cohort study assessed the antiviral efficacy of ETV/adefovir dipivoxil (ADV) combination therapy for ETV‐resistant H

Monitoring during and after antiviral th
Monitoring during and after antiviral therapy for hepatitis B
✍ Karin L. Andersson; Raymond T. Chung πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 110 KB

Recent studies suggest that long-term suppression of viral replication is critical to reducing the complications of chronic hepatitis B virus (HBV) infection. Monitoring for continued virological response during and after treatment is essential because current treatment options have limited success

Serum HBeAg quantitation during antivira
Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B
✍ Heijtink, Rudolf A.; Kruining, Johannes; Honkoop, Pieter; Kuhns, Mary C.; Hop, W πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

Hepatitis Be antigen (HBeAg) seroconversion is considered the principal short-term goal of antiviral therapy in chronic hepatitis B. To test whether the pre-and per-treatment HBeAg quantitation has a higher predictive value than that of hepatitis B virus DNA (HBV-DNA) quantitation for the outcome of

Hepatitis C virus drug resistance and im
Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy
✍ Silvana Gaudieri; Andri Rauch; Katja Pfafferott; Eleanor Barnes; Wendy Cheng; Ge πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 368 KB

The efficacy of specifically targeted anti-viral therapy for hepatitis C virus (HCV) (STAT-C), including HCV protease and polymerase inhibitors, is limited by the presence of drugspecific viral resistance mutations within the targeted proteins. Genetic diversity within these viral proteins also evol